What is this study trying to find out about Multiple Sclerosis?

This study aims to understand how blood levels of neurofilament-light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) relate to the activity and progression of Multiple Sclerosis. Researchers want to see if these proteins can help track disease changes over time. The study is sponsored by Centre Hospitalier Universitaire de Nîmes.

Who may be eligible for this Multiple Sclerosis clinical trial?

Adults aged 15 years or older with a confirmed diagnosis of Multiple Sclerosis may be eligible. The study welcomes all genders and includes people with different levels of disability and disease activity. Participants must be insured under a health plan and able to provide informed consent. Please review eligibility criteria for more details.

Is there any cost to participate in this Multiple Sclerosis clinical trial?

Study-related care, including blood tests and all trial visits, is provided at no cost. However, any personal travel or accommodation expenses are not guaranteed to be covered and may vary. Participants should plan accordingly.

Actively Recruiting

Age: 15Years +

All Genders

ID03981003

Study of Blood Levels of Neurofilament-light Chain and GFAP in Multiple Sclerosis Patients from the OFSEP Cohort at Different Disease Stages

Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2024-05-14

1150

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying serum neurofilament-light chain NfL and Glial Fibrillary Acidic Protein GFAP levels as potential markers to understand the activity and progression of Multiple Sclerosis MS at various stages of the disease. These proteins in the blood may provide insight into disability and disease changes in people living with MS. The study involves collecting blood samples from individuals diagnosed with MS who are part of the OFSEP cohort. These samples will be tested for NfL and GFAP levels at different times, including at the start and over several years, to observe how these markers relate to disease stability or progression. The study will include patients with different disease statuses, including active and stable MS. Participants will provide blood samples periodically and undergo evaluations to track disease activity and progression. Researchers will measure NfL and GFAP levels to compare patients with evolving disease to those with stable conditions over multiple time points, up to six years. The study also monitors disability levels and MRI activity, aiming to better understand MS progression. Participants involvement may last several years depending on follow-up schedules.

CONDITIONS

Brief Title

Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

Who Can Participate

Age: 15Years +

All Genders

Eligibility Criteria

You may qualify if you...

The patient has been correctly informed.
The patient has given informed and signed consent.
The patient is insured or has health insurance coverage.
The patient is at least 15 years old.
The patient has Multiple Sclerosis diagnosed according to specific criteria (Thompson et al. 2017).
The patient participates in the OFSEP-HD cohort.
The patient has an Expanded Disability Status Scale score between 0 and 7.0.
The patient may be taking Disease Modifying Drugs or not.
For Work Package 3: enrolled patients meet criteria for active MS (relapse, disability progression, or active MRI) during follow-up.
For Work Package 4: enrolled patients have stable disease in the OFSEP-HD study at Nîmes or Nantes University Hospitals.

You will not qualify if you...

Participation in another interventional study within the past three months that may affect this study's results.
The patient is currently in an exclusion period from a previous study.
The patient is under judicial protection.
The patient refuses to sign consent.
The patient cannot be adequately informed due to language or understanding barriers.
The patient is pregnant or breastfeeding.
The patient is under 15 years old.
Inability to answer questionnaires.
The patient has Clinically Isolated Syndrome that does not meet MS criteria.
The patient has Radiologically Isolated Syndrome.
The patient has Neuromyelitis optica spectrum disorder.

Research Team

Eric Thouvenot

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of Blood Levels of Neurofilament-light Chain and GFAP in Multiple Sclerosis Patients from the OFSEP Cohort at Different Disease Stages

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria